

	10/638,848
11	Filing date 8/11/03

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
TMT	5,654,307	08/05/1997	BRIDGES, ET AL.	514	258	

**EXPRESS MAIL NO. EU807711660US  
DOCKET NO. 5716-D1**

**FOREIGN PATENT DOCUMENTS**

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSL YES
TMT	96 34867	11/07/1996	WO			✓
	95 19774	07/27/1995	WO			✓
	97 38983	10/23/1997	WO			✓
	0278686	08/17/1988	EP			✓
TMT	92 20642	11/26/1992	WO			✓

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

TMT		G.W. REWCASTLE, ET AL., JOURNAL OF MEDICINAL CHEMISTRY, "TYROSINE KINASE INHIBITORS. 10. ISOMETRIC 4-[(3-BROMOPHENY)AMINO]PYRIDO[D]PYRIMIDINES ARE POTENT ATP BINDING SITE INHIBITORS OF THE TYROSINE KINASE FUNCTION OF THE EPIDERMAL GROWTH FACTOR RECEPTOR", VOL. 39, 199956PP. 1823-35, XP002046257
TMT		G.W. REWCASTLE, ET AL., JOURNAL OF MEDICINAL CHEMISTRY, "TYROSINE KINASE INHIBITORS. T. SYNTHESIS-ACTIVITY RELATIONSHIPS FOR 4-[(PHENYLMETHYL)AMINO]-AND 4-(PHENYLAMINO) QUINAZOLINES AS POTENT ADENOSINE 5'-TRIPHOSPHATE BINDING SITE INHIBITORS OF THE TYROSINE KINASE DOMAIN OF THE EPIDERMAL GROWTH FACTOR RECEPTOR", VOL. 38, 1995, PP 3482-7, XP000673491

EXAMINER	DATE CONSIDERED 4/28/05
----------	-------------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*(Use several sheets if necessary)*

**5716-01-**

~~091623,737~~

**ELLEN M. DOBRUSIN, ET AL.**

FILING DATE 8/11/03  
SEPTEMBER 9, 2000

**GROUP**

[illegible]

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
PVT	✓	96 15128	05/23/1996	WO	_____	_____	✓	
I	✓	0021292	01/07/1981	EP	_____	_____	✓	
I	✓	98 33798	08/06/1998	WO	_____	_____	✓	
I	✓	99 09030	02/25/1999	WO	_____	_____	✓	
PNT	✓	99 06378	02/11/1999	WO	_____	_____	✓	

TNT	✓	PCT INTERNATIONAL SEARCH REPORT (PCT/US99/10187), 1999.

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

view references on EAST

NOV 03 2003  
1995, no persons are regu  
PATENT 3 TRADEMARK REG

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Complete if Known**

**(Use as many sheets as necessary)**

Sheet	1	of	3
-------	---	----	---

Application Number	10/638848
Filing Date	August 11, 2003
First Named Inventor	Ellen Myra Dobrusin, et al.
Art Unit	
Examiner Name	
Attorney Docket Number	5716-D1-SRE

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>2</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
TNT	✓	WO 96/13262 A1	05-09-1996	W. J. Thompson, et al.		
I	✓	WO 99/61444 A2	12-02-1999	E. Dobrusin, et al.		
I	✓	WO 00/24744 A1	05-04-2000	W. Harris, et al.		
I	✓	WO 01/29041 A1	04-26-2001	J. P. Dunn, et al.		
I	✓	WO 01/29042 A1	04-26-2001	J. P. Dunn, et al.		
TNT	✓	WO 01/64679 A1	09-07-2001	J. L. Adams, et al.		

*Ullmann*

Date Considered

4/28/05

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.**

**USSN 10/638848 Filed 8/11/2003**  
**PD-5716-D1-SRE**



Substitute for form 1448/PTO

Complete if Known

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

2

of

3

Attorney Docket Number

5716-D1-SRE

Application Number

10/638848

Filing Date

August 11, 2003

First Named Inventor

Ellen Myra Dobrusin, et al.

Art Unit

Examiner Name

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
TNT	✓	K. ADACHI, "Synthesis of Orcinol Monomethyl Ether", Memoirs of the Osaka Institute of Technology, Series A, 1983 pp 33-41, Vol. 28, No. 1	
	✓	J. G. CAPPUCCINO, et al., "Growth Inhibition of Clostridium fesceri by Carcinostatic Purine and Pyrimidine Analogs", Cancer Res., 1964, pp 1243-1248, Vol. 24, No. 7	
	✓	S. K. CHATTERJEE, et al., "Synthesis of Some 4-Oxy & 2:4-Dioxypyrimido-(4,5-d)-Pyrimidines", J. Sci. Industr. Res., 1958, pp. 63-70, Vol. 17B	
	✓	S. K. CHATTERJI, et al., "Synthesis of Some Pyrimido(4,5-d)Pyrimidines as Potential Purine Antagonists", J. Sci. Industr. Res., 1959, pp 272-278, Vol. 18B	
	✓	N. A. DEVI et al., "Synthesis of Pyrimido [4,5-d] Pyrimidines as Antifungal Agents" Indian Journal of Heterocyclic Chemistry, 1998, pp 193-196, Vol. 7	
	✓	H. GRABOYES et al., "Pteridienes. X. Some Pyrimidopyrimidine Isomers of Triamterene", 1968, pp 568-573, Vol 11	
	✓	K. GROHE, et al., "Syenthesse und Reaktionen von Pyrimido[4,5-d]pyrimidinen", Leibigs Ann. Chem., 1974, pp 2066-2073	
	✓	A. V. GULEVSKAYA et al., "Purines, Pyrimidines, and Condensed Systems Based on These Compounds Chemistry of Heterocyclic Compounds 12, 1994, pp 1083-1086, Vol. 30, No. 9	
	✓	A. V. GULEVSKAYA et al., "Purines, Pyrimidines, and Condensed Systems Based on These Compounds Chemistry of Heterocyclic Compounds 13, 1994, pp 1087-1091, Vol. 30, No. 9	
TNT	✓	K. HIROTA, et al., "A Facile Synthesis of 7-Substituted Pyrimido[4,5-d]-pyrimidine-2,4-diones" Synthesis, 1984, pp. 589-590	

Examiner  
SignatureDate  
Considered

4/28/05

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Applicati n Number	10/638848
Filing Date	August 11, 2003
First Named Inventor	Ellen Myra Dobrusin, et al.
Art Unit	
Examiner Name	
Attorney Docket Number	5716-D1-SRE

Sheet 3 of 3

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
TNT	✓	K. HIROTA et al, "Novel Rung Transformations of 5-Cyanouracils into 2-Thiocytosines, 2,4-Diaminopyrimidines, and Pyrimido[4,5-d]pyrimidines by the Reaction with Thioureas and Guanidines", J. Chem. Soc. Perkins Trans. 1, 1990, pp 123-128 .	
	✓	A. MARSH, et al., :Self-complementary hydrogen bonding heterocycles designed for the enforced self-assembly into supramolecular Macrocycles", Chem. Commun., 1996, pp 1527-1528, Vol. 13 .	
	✓	T. MASQUELIN, et al., a Novel Solution and Solid-Phase Appriach to 2,4,5-Tri- and 2,4,5,6-Tetra-substituted Pyrimidines and Their Conversion into Condensed Heterocycles", Helvetica Chemica Acta, 1998, pp 646-660, Vol. 81.No. 4 .	
	✓	E. C. TAYLOR, et al., "Pyrimido [4,5-d]pyrimidines Part I", J. Am. Chem. Soc., 1960, pp 5711-5718, Vol. 82 .	
	✓	Y. TOMINAGA et al., "Synthesis of Pyrimido[4,5-d]Pyrimidines", Heterocycles, 1979, 2 pgs, Vol. 12, No. 4 .	
	✓	Y. TOMINAGA, et al., "Reaction of 6-Aminouracils with Ketenethioacetals", Chem. Pharm. Bull., 1984, pp 122-129, Vol. 32, No. 1 .	
	✓	H. WAMHOFF, et al., "Pyrimido[4,5-d]Pyrimidines, Pyrimido[4',5':4,5]Pyrimido[6,1-a]-Azepines, and an Imidazos[5,1-f][1,2,4]Triazine by Three Component Reaction", Heterocycles, Vol. 35, No. 2, 1993, pp 1055-1066 .	
TNT	✓	R. EVERA, et al., "Zum Reaktionsverhalten der Thio-bis-formaidine; Versuche zur Synthese von Pyrimidino[4,5-d]pyrimidin-derivaten", Z. Chem., pp 412-413, Vol. 20. Jg .	

Examiner Signature		Date Considered	4/28/05
-----------------------	--	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

USPN 10/638848 Filed 8/11/2003  
PD-5716-D1-SRE